Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
Judith Stickdorn, Lara Stein, Danielle Arnold-Schild, Jennifer Hahlbrock, Carolina Medina‐Montano, Joschka Bartneck, Tanja Ziß, Evelyn Montermann, Cinja Kappel, Dominika Hobernik, Maximilian Haist, Hajime Yurugi, Marco Raabe, A. Best, Krishnaraj Rajalingam, Markus P. Radsak, Sunil A. David, Kaloian Koynov, Matthias Bros, Stephan Grabbe, Hansjörg Schild, Lutz Nuhn
Abstract
. The underlying chemical design allows for straightforward covalent attachment of a model antigen (ovalbumin) and an immune adjuvant (imidazoquinoline-type TLR7/8 agonist) onto the same nanocarrier system. In addition to eliciting antigen-specific T and B cell responses that outperform mixtures of individual components, our two-component nanovaccine leads in prophylactic and therapeutic studies to an antigen-specific growth reduction of different tumors expressing ovalbumin intracellularly or on their surface. Regarding the versatile opportunities for functionalization, our nanogels are promising for the development of highly customized and potent nanovaccines.